NNC45-0781

• CAT Number: I013314
• CAS Number: 207277-66-5
• Molecular Formula: C₂₇H₂₉NO₃
• Molecular Weight: 415.52
• Purity: ≥95%
• Target: Estrogen Receptor/ERR
• Solubility: DMSO
• IUPAC Name: (3S,4R)-3-phenyl-4-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3,4-dihydro-2H-chromen-7-ol
• InChI: InChI=1S/C27H29NO3/c29-22-10-13-24-26(18-22)31-19-25(20-6-2-1-3-7-20)27(24)21-8-11-23(12-9-21)30-17-16-28-14-4-5-15-28/h1-3,6-13,18,25,27,29H,4-5,14-17,19H2/t25-,27-/m1/s1
• InChIKey: FEVZKAOFFCUDLI-XNMGPUDCSA-N
• SMILES: C1CCN(C1)CCOC2=CC=C(C=C2)[C@H]3[C@H](COC4=C3C=CC(=C4)O)C5=CC=CC=C5

NNC45-0781（Cat No.:I013314）is an investigational small-molecule drug being developed by Novo Nordisk as a potential treatment for diabetes. It is a selective GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, designed to enhance insulin secretion in response to meals, while also improving glucose control. GIP plays a role in regulating insulin and glucagon secretion, and NNC45-0781 aims to harness this pathway to achieve better blood glucose control. This drug is being explored for its ability to improve both type 2 diabetes and obesity outcomes, potentially offering a new class of treatment alongside other therapies like GLP-1 receptor agonists.

Reference

[1]. Bury PS, et al. Synthesis and pharmacological evaluation of novel cis-3,4-diaryl-hydroxychromanes as high affinity partial agonists for the estrogen receptor. Bioorg Med Chem. 2002 Jan;10(1):125-45.